Can-Fite BioPharma (NYSE:CANF) Upgraded at StockNews.com

StockNews.com upgraded shares of Can-Fite BioPharma (NYSE:CANF) from a sell rating to a hold rating in a research note published on Tuesday.

Other analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday. EF Hutton Acquisition Co. I raised shares of Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th.

Can-Fite BioPharma Stock Performance

CANF stock traded up $0.06 during trading on Tuesday, hitting $2.05. 2,804 shares of the stock traded hands, compared to its average volume of 67,408. Can-Fite BioPharma has a 1 year low of $1.83 and a 1 year high of $4.69. The firm’s 50 day moving average is $2.26 and its two-hundred day moving average is $2.52.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC lifted its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.